Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase EARLY_PHASE1 1

Status

Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Tumor-Agnostic 1

Conditions

Breast Neoplasms 2Estrogen Receptor Positive Breast Cancer 1

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 486Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 152Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
proto-oncogene protein c-fes-fps × Breast × Clear all
NCT01957332 2024-11-20

IMPACT-MBC

University Medical Center Groningen

Phase NA Active not recruiting
217 enrolled
Breast

Breast Neoplasms

NCT04727632 2024-10-28

[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial

University of Utah

Phase EARLY_PHASE1 Terminated
2 enrolled
Breast

Estrogen Receptor Positive Breast Cancer

NCT01714128 2021-10-25

FES-PET for Patients Treated on NCI Protocol 8762

Washington University School of Medicine

Phase NA Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡